Stocks of Revance Therapeutics Inc. (NASDAQ:RVNC) traded higher last session on Wall Street, down -0.65% to $24.60.
According to the data, Revance Therapeutics Inc. (NASDAQ:RVNC) has 12 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $21.00, we find $41.00. Given the previous closing price of $24.76, this indicates a potential upside of 65.59 percent. RVNC stock price is now -18.77% away from the 50-day moving average and -12.62% away from the 200-day moving average. The market capitalization of the company currently stands at $2.06B.
A total of 1 analysts have issued a hold rating and 9 have given it a buy rating. Brokers who have rated the stock have averaged $40.58 as their price target over the next twelve months.
With the price target of $27, Morgan Stanley recently initiated with Equal-Weight rating for Revance Therapeutics Inc. (NASDAQ: RVNC).
In other news, Foley Mark J, CEO sold 26,279 shares of the company’s stock on Jul 03. The stock was sold for $655,333 at an average price of $24.94. Upon completion of the transaction, the CEO now directly owns 866,654 shares in the company, valued at $21.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 03, CFO Schilke Tobin sold 1,701 shares of the business’s stock. A total of $42,593 was realized by selling the stock at an average price of $25.04. This leaves the insider owning 79,896 shares of the company worth $1.97 million. Insiders disposed of 375,356 shares of company stock worth roughly $9.23 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RVNC stock. A new stake in Revance Therapeutics Inc. shares was purchased by GREAT LAKES ADVISORS, LLC during the first quarter worth $7,378,000. LORD, ABBETT & CO. LLC invested $5,702,000 in shares of RVNC during the first quarter. In the first quarter, CANADA PENSION PLAN INVESTMENT BOARD acquired a new stake in Revance Therapeutics Inc. valued at approximately $4,122,000. NORGES BANK acquired a new stake in RVNC for approximately $3,961,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in RVNC valued at around $3,234,000 in the second quarter. In total, there are 281 active investors with 89.40% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $24.74 for Revance Therapeutics Inc. (NASDAQ: RVNC). During the past 12 months, Revance Therapeutics Inc. has had a low of $14.14 and a high of $37.98. The fifty day moving average price for RVNC is $30.15 and a two-hundred day moving average price translates $28.15 for the stock.
The latest earnings results from Revance Therapeutics Inc. (NASDAQ: RVNC) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.74, missing analysts’ expectations of -$0.7 by -0.04. This compares to -$0.94 EPS in the same period last year. The company reported revenue of $49.33 million for the quarter, compared to $25.26 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 95.29 percent. For the current quarter, analysts expect RVNC to generate $59.35M in revenue.
Revance Therapeutics Inc.(RVNC) Company Profile
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
